ChromaDex (CDXC) PT Raised 90% to $17 at Oppenheimer

March 12, 2021 9:05 AM EST
Get Alerts CDXC Hot Sheet
Price: $8.20 -3.87%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 17 | Down: 13 | New: 41
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Oppenheimer analyst Brian Nagel raised the price target on ChromaDex (NASDAQ: CDXC) to $17.00 (from $9.00) after the company announced Q4 results that were in line with expectations. EBITDA, of $1.1M rose from ($2.1M) the prior year, and came in modestly better than expectations for ($1.3M). CDXC did not provide specific financial guidance, management did indicate that a key objective for 2021 is to deliver positive adj. EBITDA, excluding legal expenses.

The analyst reiterated the Outperform rating, stating "we have highlighted CDXC as a still “below the radar,” high-quality, albeit speculative play within consumer healthcare. Overall, we look upon recent trends at ChromaDex and commentary from management as suggestive of a company solidifying a base, which should over time support better adoption of its core Tru Niagen product, and hence sustained, outsized sales and profit expansion. Its new partnership with WMT, while not necessarily a game-changer, we believe represents another significant step forward on CDXC's part to bring Tru Niagen to a much wider consumer audience."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change